Q4 2025 · 13F-HR
Paradigm Biocapital Advisors LPholdings as filed
Filed 2026-02-17 · accession 0001855655-26-000003
$3.92B
Reported value
30
Positions
2025-12-31
Period end
The Brief · Paradigm Biocapital Advisors LP · Q4 2025
AI · grounded in 13F
Paradigm Biocapital Advisors LP closed its position in Merus N V 2GH, reducing exposure by $440.03M. The fund also exited positions in Agios Pharmaceuticals Inc AGIO and Janux Therapeutics Inc JANX, which decreased holdings by $115.34M and $71.37M respectively. On the buy side, the fund increased its share count in Genmab A/S GMAB by 84.44% and SPDR Series Trust XBI by 50.0%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 670703107 | NUVL | NUVALENT INC | $530.1M | 13.5% | 5,269,433 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $529.2M | 13.5% | 6,644,403 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $373.2M | 9.53% | 5,724,016 | Common | SOLE |
| 372303206 | GMAB | GENMAB A/S | $216.8M | 5.53% | 7,039,834 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $209.8M | 5.35% | 2,562,154 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $191.2M | 4.88% | 1,417,473 | Common | SOLE |
| 68062P106 | OLMA | OLEMA PHARMACEUTICALS INC | $188.6M | 4.81% | 7,544,172 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $187.7M | 4.79% | 4,068,020 | Common | SOLE |
| 78464A870 | XBI | SPDR SERIES TRUST | $182.9M | 4.67% | 1,500,000 | PUT | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $167.8M | 4.28% | 759,565 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $162.3M | 4.14% | 6,541,210 | Common | SOLE |
| 80706P103 | SRRK | SCHOLAR ROCK HLDG CORP | $134.9M | 3.44% | 3,062,157 | Common | SOLE |
| M96088105 | URGN | UROGEN PHARMA LTD | $104.8M | 2.67% | 4,473,648 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $102.9M | 2.63% | 2,210,774 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $84.8M | 2.16% | 1,123,243 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT INC | $67.4M | 1.72% | 3,691,475 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $52.7M | 1.34% | 14,159,095 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $52.3M | 1.34% | 684,277 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $51.8M | 1.32% | 1,710,316 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $48.1M | 1.23% | 1,467,266 | Common | SOLE |
| 52886X107 | LXEO | LEXEO THERAPEUTICS INC | $47.3M | 1.21% | 4,763,198 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $44.9M | 1.15% | 1,443,102 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $35.6M | 0.91% | 2,935,284 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $32.7M | 0.84% | 810,286 | Common | SOLE |
| 107924102 | BBOT | BRIDGEBIO ONCOLOGY THERAPEUT | $28.3M | 0.72% | 2,261,749 | Common | SOLE |
| 929033207 | VOR | VOR BIOPHARMA INC | $22.9M | 0.58% | 1,750,000 | Common | SOLE |
| 045396207 | ASMB | ASSEMBLY BIOSCIENCES INC | $22.6M | 0.58% | 665,251 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $19.6M | 0.50% | 2,401,217 | Common | SOLE |
| 46124U107 | IVA | INVENTIVA SA | $18.6M | 0.47% | 4,000,000 | Common | SOLE |
| 482929106 | KLRS | KALARIS THERAPEUTICS INC | $5.9M | 0.15% | 700,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.